NovaBay Pharmaceuticals, Inc.
NBY · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $10 | $14 | $10 |
| % Growth | -6.4% | -27.4% | 41.2% | – |
| Cost of Goods Sold | $3 | $4 | $7 | $4 |
| Gross Profit | $6 | $6 | $8 | $7 |
| % Margin | 66.3% | 58.2% | 54% | 63.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $7 | $5 | $7 | $7 |
| SG&A Expenses | $11 | $10 | $15 | $15 |
| Sales & Mktg Exp. | $4 | $5 | $8 | $8 |
| Other Operating Expenses | $1 | $0 | $7 | $0 |
| Operating Expenses | $12 | $10 | $22 | $15 |
| Operating Income | -$6 | -$4 | -$14 | -$9 |
| % Margin | -59.7% | -39.2% | -100.1% | -86.8% |
| Other Income/Exp. Net | -$1 | -$2 | $4 | $3 |
| Pre-Tax Income | -$7 | -$6 | -$11 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$10 | -$11 | -$6 |
| % Margin | -73.8% | -92.2% | -73.6% | -57.1% |
| EPS | -2.53 | -139.14 | -353.59 | -184.09 |
| % Growth | 98.2% | 60.6% | -92.1% | – |
| EPS Diluted | -2.53 | -138.65 | -353.59 | -184.09 |
| Weighted Avg Shares Out | 3 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $2 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$4 | -$7 | -$9 |
| % Margin | -60.6% | -39.2% | -50% | -85.7% |